Allosteric Modulation of Purine and Pyrimidine Receptors

Advances in Pharmacology

Volumn 61, Issue , 2011, Pages 187-220

  Jacobson, Kenneth A ^a   Gao, Zhan Guo ^a   Göblyös, Anikó ^b   IJzerman, Adriaan P ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adenosine receptors; Allostery; G protein coupled receptors; Ion channels; P2Y receptors; Purines

Indexed keywords

1H IMIDAZO[4,5 C]QUINOLIN 4 AMINE; 2 AMINO 3 (3 CHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 3 (3,4 DICHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 3 AROYLTHIOPHENE DERIVATIVE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2 ARACHIDONOYLGLYCEROL; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2,4 DISUBSTITUTED QUINOLOINE; 3 (2 PYRIDINYL)ISOQUINOLONE; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 4 METHOXY N [7 METHYL 3 (2 PYRIDINYL) 1 ISOQUINOLINYL]BENZAMIDE; 4 METHYL 2 OXO 2H CHROMEN 7 YL METHYLCARBAMATE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 (N,N HEXAMETHYLENE)AMILORIDE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ABA X BY 630; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR AFFECTING AGENT; CYCLIC AMP; FOOD DYE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND GATED ION CHANNEL; LUF 6000; LUF 6096; LUF 6258; MITOGEN ACTIVATED PROTEIN KINASE; MRS 2801; MRS 5049; MRS 5190; MRS 542; N (2,3 DIPHENYL 1,2,4 THIADIAZOL 5(2H) YLIDENE)METHANAMINE; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; N [3 (2 PYRIDINYL) 1 ISOQUINOLINYL]BENZAMIDE; N[2,3 DIPHENYL 1,2,4 THIADIAZOL 5 (2H) YLIDENE]METHANAMINE; PD 120918; PSB 603; PURINERGIC P2X RECEPTOR; PURINERGIC P2Y RECEPTOR; T 62; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VCP 333; VCP 520; VUF 8504;

ALLOSTERISM; BINDING AFFINITY; BOOK; BRAIN; CHRONIC PAIN; DNA SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; HEART; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIASIS; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RNA TRANSLATION; SECOND MESSENGER; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

EID: 79955947758     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385526-8.00007-2     Document Type: Chapter

References (123)

1. 3 receptors by Cibacron blue. The Journal of Pharmacology and Experimental Therapeutics 1999, 291:1135-1142.
2. 12 receptor. Journal of Thrombosis and Haemostasis 2008, 6:1908-1914.
3. Amoah-Apraku B., Xu J., Lu J.Y., Pelleg A., Bruns R.F., Belardinelli L. Selective potentiation by an A1 adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart. The Journal of Pharmacology and Experimental Therapeutics 1993, 266:611-617.
4. 1 adenosine receptor binding. Organic & Biomolecular Chemistry 2007, 5:1276-1281.
5. Aurelio L., Valant C., Figler H., Flynn B.L., Linden J., Sexton P.M., Christopoulos A., Scammells P.J. 3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. Bioorganic & Medicinal Chemistry 2009, 17:7353-7361.
6. 1 receptor: Synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. Journal of Medicinal Chemistry 2009, 52:4543-4547.
7. 1 adenosine receptor modulation. Journal of Medicinal Chemistry 2010, 53:6550-6559.
8. Ballesteros J.A., Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods in Neurosciences 1995, 25:366-428.
9. 1 adenosine receptor. Mini Reviews in Medicinal Chemistry 2007, 7:559-569.
10. 1 receptor. European Journal of Medicinal Chemistry 2004, 39:855-865.
11. 1 adenosine receptor. Journal of Medicinal Chemistry 2003, 46:794-809.
12. 1 adenosine receptor. Bioorganic & Medicinal Chemistry Letters 2000, 10:1953-1957.
13. 1 adenosine receptor: Influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Molecular Pharmacology 1996, 50:1635-1642.
14. Besada P., Mamedova L., Thomas C.J., Costanzi S., Jacobson K.A. Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality. Organic & Biomolecular Chemistry 2005, 3:2016-2025.
15. Bhattacharya S., Linden J. The allosteric enhancer, PD 81,723, stabilizes human A1 adenosine receptor coupling to G proteins. Biochimica et Biophysica Acta 1995, 1265:15-21.
16. Bhattacharya S., Linden J. Effects of long-term treatment with the allosteric enhancer, PD81,723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors. Molecular Pharmacology 1996, 50:104-111.
17. Bhattacharya S., Youkey R.L., Ghartey K., Leonard M., Linden J., Tucker A.L. The allosteric enhancer PD 81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs. The Biochemical Journal 2006, 396:139-146.
18. 2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. Journal of Medicinal Chemistry 2009, 52:3994-4006.
19. Brake A.J., Wagenbach M.J., Julius D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 1994, 371:519-523.
20. Brandts B., Bünemann M., Hluchy J., Sabin G.V., Pott L. Inhibition of muscarinic K+ current in guinea-pig atrial myocytes by PD 81,723, an allosteric enhancer of adenosine binding to A1 receptors. British Journal of Pharmacology 1997, 121:1217-1223.
21. Broch-Lips M., Pedersen T.H., Nielsen O.B. Effect of purinergic receptor activation on Na+-K+ pump activity, excitability, and function in depolarized skeletal muscle. American Journal of Physiology. Cell Physiology 2010, 298:C1438-C1444.
22. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Molecular Pharmacology 1990, 38:939-949.
23. 1 receptor binding by 2-amino-3-benzoylthiophenes. Molecular Pharmacology 1990, 38:950-958.
24. Bruns R.F., Lu G.H. Enhancement of adenosine agonist binding by a substituted 1-benzopyran-2-one. Adenosine receptors in the nervous system 1989, Taylor and Francis, London, p. 192. J.A. Ribeiro (Ed.).
25. 1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release. European Journal of Pharmacology 2002, 454:177-182.
26. Cao X., Phillis J.W. Adenosine A1 receptor enhancer, PD 81,723, and cerebral ischemia/reperfusion injury in the gerbil. General Pharmacology 1995, 26:1545-1548.
27. Changeux J.P. Allosteric receptors: From electric organ to cognition. Annual Review of Pharmacology and Toxicology 2010, 50:1-38.
28. 1 receptor coupling to G-proteins in brain. Journal of Neurochemistry 2005, 93:715-723.
29. Chordia M.D., Zigler M., Murphree L.J., Figler H., Macdonald T.L., Olsson R.A., Linden J. 6-aryl-8H-indeno[1,2-d]thiazol-2- ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency. Journal of Medicinal Chemistry 2005, 48:5131-5139.
30. Christopoulos A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nature Reviews. Drug Discovery 2002, 1:198-210.
31. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacological Reviews 2002, 54:323-374.
32. 4 receptor channel: Critical roles of Cys-132 for zinc-potentiation and Asp-138 for copper-inhibition. The Journal of Biological Chemistry 2007, 282:36879-36886.
33. Coddou C., Yan Z., Obsil T., Huidobro-Toro J.P., Stojilkovic S.S. Activation and regulation of purinergic P2X receptor channels. Pharmacological Reviews 2011, (submitted for publication).
34. Conn P.J., Christopoulos A., Lindsley C.W. Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nature Reviews. Drug Discovery 2009, 8:41-54.
35. Cosyn L., Van Calenbergh S., Joshi B.V., Ko H., Carter R.L., Harden T.K., Jacobson K.A. Synthesis and P2Y receptor activity of nucleotide 5'-phosphonate derivatives. Bioorganic & Medicinal Chemistry Letters 2009, 19:3002-3005.
36. De Ligt R.A.F., Rivkees S.A., Lorenzen A., Leurs R., IJzerman A.P. A "locked-on", constitutively active mutant of the adenosine A1 receptor. European Journal of Pharmacology 2005, 510:1-8.
37. Evans R.J. Orthosteric and allosteric binding sites of P2X receptors. European Biophysics Journal 2009, 38:319-327.
38. Fawzi A.B., Macdonald D., Benbow L.L., Smith-Torhan A., Zhang H., Weig B.C., Ho G., Tulshian D., Linder M.E., Graziano M.P. SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Molecular Pharmacology 2001, 59:30-37.
39. 1 receptor modulators and antagonists. Journal of Medicinal Chemistry 2008, 51:6165-6172.
40. Figler H., Olsson R.A., Linden J. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract guanine nucleotide effects on agonist binding. Molecular Pharmacology 2003, 64:1557-1564.
41. Fredholm B.B., IJzerman A.P., Jacobson K.A., Linden J., Müller C. Nomenclature and classification of adenosine receptors-An update. Pharmacological Reviews 2011, 63:1-34.
42. Gao Z.G., Gross A.S., Jacobson K.A. Effects of SCH-202676 on adenosine and P2Y receptors. Life Sciences 2004, 74:3173-3180.
43. 2A adenosine receptors by amiloride analogues and sodium ions. Biochemical Pharmacology 2000, 60:669-676.
44. 3 adenosine receptor. Molecular Pharmacology 2003, 63:1021-1031.
45. Gao Z.G., Kim S.K., IJzerman A.P., Jacobson K.A. Allosteric modulation of the adenosine family of receptor. Mini Reviews in Medicinal Chemistry 2005, 5:545-553.
46. 3 adenosine receptors by a series of imidazoquinoline derivatives. Molecular Pharmacology 2002, 62:81-89.
47. Gao Z.G., Mamedova L., Tchilibon S., Gross A.S., Jacobson K.A. 2, 2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. Biochemical Pharmacology 2004, 68:231-237.
48. 3 adenosine receptors. Biochemical Pharmacology 2003, 65:525-534.
49. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Molecular Pharmacology 2001, 60:1057-1063.
50. Gao Y., Xu C., Liang S., Zhang A., Mu S., Wang Y., Wan F. Effect of tetramethylpyrazine on primary afferent transmission mediated by P2X3 receptor in neuropathic pain states. Brain Research Bulletin 2008, 77:27-32.
51. 3 adenosine receptor by an imidazoquinoline allosteric enhancer LUF6000 and its analogues. BMC Pharmacology 2008, 8:20.
52. 6 -1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: Synthesis and biological evaluation as allosteric modulators of A2A adenosine receptors. European Journal of Medicinal Chemistry 2008, 43:1639-1647.
53. 3 adenosine receptor. Journal of Medicinal Chemistry 2006, 49:3354-3361.
54. Göblyös A., IJzerman A.P. Allosteric modulation of adenosine receptors. Purinergic Signalling 2009, 5:51-61.
55. Göblyös A., Santiago S.N., Pietra D., Mulder-Krieger T., von Frijtag Drabbe Künzel J., Brussee J., IJzerman A.P. Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers. Bioorganic & Medicinal Chemistry 2005, 13:2079-2087.
56. Harrington P.E., Fotsch C. Calcium sensing receptor activators: Calcimimetics. Current Medicinal Chemistry 2007, 14:3027-3034.
57. 3 receptor. Journal of Medicinal Chemistry 2009, 52:926-931.
58. 1 receptors of LUF5831, a novel nonadenosine-like agonist. British Journal of Pharmacology 2006, 147:533-541.
59. 2A adenosine receptor bound to an antagonist. Science 2008, 322:1211-1217.
60. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nature Reviews. Drug Discovery 2006, 5:247-264.
61. Janusz C.A., Berman R.F. The adenosine binding enhancer, PD 81,723, inhibits epileptiform bursting in the hippocampal brain slice. Brain Research 1993, 619:131-136.
62. Janusz C.A., Bruns R.F., Berman R.F. Functional activity of the adenosine binding enhancer, PD 81,723, in the in vitro hippocampal slice. Brain Research 1991, 567:181-187.
63. Jarvis M.F., Gessner G., Shapiro G., Merkel L., Myers M., Cox B.F., Martin G.E. Differential effects of the adenosine A1 receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes. Brain Research 1999, 840:75-83.
64. Kawate T., Michel J.C., Birdsong W.T., Gouaux E. Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 2009, 460:592-599.
65. 4 receptor channels. The Journal of Neuroscience 1999, 19:7289-7299.
66. 1 adenosine receptor antagonists, agonists and allosteric enhancers. Adenosine receptors in health and disease, Handbook of experimental pharmacology 2009, 25-58. Springer-Verlag, Berlin, Heidelberg. C.N. Wilson, S.J. Mustafa (Eds.).
67. 3 adenosine receptor. Journal of Medicinal Chemistry 2009, 52:2098-2108.
68. 2 purinoceptor revealed by changing extracellular pH. British Journal of Pharmacology 1996, 117:1371-1373.
69. 1 receptor and different 351Cys-mutated Gi alpha-subunits. European Journal of Pharmacology 2004, 499:91-98.
70. 1 receptors. European Journal of Pharmacology 2005, 522:1-8.
71. Kollias-Baker C., Ruble J., Dennis D., Bruns R.F., Linden J., Belardinelli L. Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circulation Research 1994, 75:961-971.
72. 1 receptor. The Journal of Pharmacology and Experimental Therapeutics 1997, 281:761-768.
73. Kollias-Baker C., Xu J., Pelleg A., Belardinelli L. Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine. Circulation Research 1994, 75:972-980.
74. Kourounakis A.P., van de Klein P.A.M., IJzerman A.P. Elucidation of stucture-activity relationships of 2-amino-3-benzoylthiophenes: Study of their allosteric enhanceing vs. antagonistic activity on adenosine A1 receptors. Drug Development Research 2000, 49:227-237.
75. Kourounakis A., Visser C., de Groote M., IJzerman A.P. Differential effects of the allosteric enhancer (2-amino-4,5-dimethyltrienyl)[ 3-(trifluoromethyl)phenyl] methanone (PD 81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. Biochemical Pharmacology 2001, 61:137-144.
76. 2A receptor-mediated anion secretion in colon epithelial cells. Experimental Cell Research 2009, 315:3028-3035.
77. 3 adenosine receptor. Biochemical Pharmacology 2010, 79:48-56.
78. Leung E., Walsh L.K., Kim E.J., Lazar D.A., Seran C.S., Wong E.H., Eglen R.M. Enhancement of the adenosine A receptor functions by benzoylthiophenes in guinea pig tissues in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology 1995, 352:206-212.
79. Lewandowicz A.M., Vepsäläinen J., Laitinen J.T. The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms. British Journal of Pharmacology 2006, 147:422-429.
80. Li X., Conklin D., Pan H.-L., Eisenach J.C. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. The Journal of Pharmacology and Experimental Therapeutics 2003, 305:950-955.
81. 2+ in rat nodose ganglion neurons. Journal of Neurophysiology 1996, 76:3048-3058.
82. Lorca R.A., Coddou C., Gazitua M.C., Bull P., Arredondo C., Huidobro-Toro J.P. Extracellular histidine residues identify common structural determinants in the copper/zinc P2X2 receptor modulation. Journal of Neurochemistry 2005, 95:499-512.
83. Mamedova L., Capra V., Accomazzo M.R., Gao Z.G., Ferrario S., Fumigalli M., Abbracchio M.P., Rovati G.E., Jacobson K.A. CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochemical Pharmacology 2005, 71:115-125.
84. Martynyuk A.E., Zima A., Seubert C.N., Morey T.E., Belardinelli L., Dennis D.M. Potentiation of the negative dromotropic effect of adenosine by rapid heart rates: Possible ionic mechanism. Basic Research in Cardiology 2002, 97:295-304.
85. 3 receptor pharmacology by the food dye brilliant black BN: Evidence for allosteric interactions. Molecular Pharmacology 2010, 77:678-686.
86. May L.T., Self T.J., Briddon S.J., Hill S.J. The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells. Molecular Pharmacology 2010, 78:511-523.
87. Meno J.R., Higashi H., Cambray A.J., Zhou J., D'Ambrosio R., Winn H.R. Hippocampal injury and neurobehavioral deficits are improved by PD 81,723 following hyperglycemic cerebral ischemia. Experimental Neurology 2003, 183:188-196.
88. 4 receptor. Neuropharmacology 1998, 37:1579-1586.
89. Mizumura T., Auchampach J.A., Linden J., Bruns R.F., Gross G.J. PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circulation Research 1996, 79:415-423.
90. Mohr K., Tränkle C., Kostenis E., Barocelli E., De Amici M., Holzgrabe U. Rational design of dualsteric GPCR ligands: Quests and promise. British Journal of Pharmacology 2010, 159:997-1008.
91. Mudumbi R.V., Montamat S.C., Bruns R.F., Vestal R.E. Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. The American Journal of Physiology 1993, 264:H1017-H1022.
92. Musser B., Mudumbi R.V., Liu J., Olson R.D., Vestal R.E. Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. The Journal of Pharmacology and Experimental Therapeutics 1999, 288:446-454.
93. 2 receptors. The Journal of Biological Chemistry 2005, 280:25982-25993.
94. 1 receptor. Journal of Medicinal Chemistry 2010, 53:3028-3037.
95. 1 receptor allosteric enhancers. Bioorganic & Medicinal Chemistry 2006, 14:2358-2365.
96. Patel K., Barnes A., Camacho J., Paterson C., Boughtflower R., Cousens D., Marshall F. Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. European Journal of Pharmacology 2001, 430:203-210.
97. Phillis J.W., Smith-Barbour M., Perkins L.M., O'Regan M.H. Characterization of glutamate, aspartate, and GABA release from ischemic rat cerebral cortex. Brain Research Bulletin 1994, 34:457-466.
98. 4 receptor channels. The Journal of General Physiology 2004, 123:281-293.
99. Romagnoli R. Synthesis and biological characterization of [3H](2-amino-4,5,6, 7-tetrahydrobenzo[b]thiophen-3-yl)-(4-chlorophenyl)-methanone, the first radiolabelled adenosine A1 allosteric enhancer. Bioorganic & Medicinal Chemistry 2006, 16:1402-1404.
100. 1 adenosine receptor. Journal of Medicinal Chemistry 2008, 51:5875-5879.
101. Romagnoli R., Baraldi P.G., Moorman A.R., Iaconinoto M.A., Carrion M.D., Cara C.L., Tabrizi M.A., Preti D., Fruttarolo F., Baker S.P., Varani K., Borea P.A. Microwave-assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A1 receptor. Bioorganic & Medicinal Chemistry 2006, 16:5530-5533.
102. 1 adenosine receptors: State of the art and new horizons for drug development. Current Medicinal Chemistry 2010, 17:3488-3502.
103. Schwartz T.W., Holst B. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. Journal of Receptors and Signal Transduction 2006, 26:107-128.
104. Seguela P., Haghighi A., Soghomonian J.-J., Cooper E. A novel neuronal P2X ATP receptor ion channel with widespread distribution in the brain. The Journal of Neuroscience 1996, 16:448-455.
105. Shen J., Halenda S.P., Sturek M., Wilden P.A. Novel mitogenic effect of adenosine on coronary artery smooth muscle cells: Role for the A1 adenosine receptor. Circulation Research 2005, 96:982-990.
106. Silberberg S.D., Li M., Swartz K.J. Ivermectin interaction with transmembrane helices reveals widespread rearrangements during opening of P2X receptor channels. Neuron 2007, 54:263-274.
107. 4 : An ATP-activated ionotropic receptor cloned from rat brain. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:3684-3688.
108. Spedding M., Menton K., Markham A., Weetman D.F. Antagonists and the purinergic nerve hypothesis: 2,2'-pyridylisatogen tosylate (PIT), an allosteric modulator of P2Y receptors. A retrospective on a quarter century of progress. Journal of the Autonomic Nervous System 2000, 81:225-227.
109. Stewart G.D., Sexton P.M., Christopoulos A. Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae. Molecular Pharmacology 2010, 78:205-214.
110. Stoop R., Surprenant A., North R.A. Different sensitivities to pH of ATP-induced currents at four cloned P2X receptors. Journal of Neurophysiology 1997, 78:1837-1840.
111. 4 receptors reveal a novel mechanism of ligand-gated channel facilitation by ivermectin. Molecular Pharmacology 2006, 69:576-587.
112. 1 receptor allosteric modulators. Molecular Pharmacology 2010, 78:444-455.
113. Valant C., Sexton P.M., Christopoulos A. Orthosteric/allosteric bitopic ligands: Going hybrid at GPCRs. Molecular Interventions 2009, 9:125-135.
114. van den Nieuwendijk A.M., Pietra D., Heitman L., Göblyös A., IJzerman A.P. Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. Journal of Medicinal Chemistry 2004, 47:663-672.
115. 1 receptor: Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. Journal of Medicinal Chemistry 1999, 42:3629-3635.
116. van Galen P.J., Nissen P., van Wijngaarden I., IJzerman A.P., Soudijn W. 1H-imidazo[4,5-c]quinolin-4-amines: Novel non-xanthine adenosine antagonists. Journal of Medicinal Chemistry 1991, 34:1202-1206.
117. 3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. Journal of Medicinal Chemistry 1998, 41:3987-3993.
118. Virginio C., Church D., North R.A., Surprenant A. Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor. Neuropharmacology 1997, 36:1285-1294.
119. 2 receptors and its dependence on extracellular pH. British Journal of Pharmacology 1998, 123:1214-1220.
120. 3 receptors. British Journal of Pharmacology 1999, 128:486-492.
121. 4 receptor function. Journal of Neurophysiology 1999, 81:2088-2094.
122. Yang H., Rotstein D.M. Novel CCR5 antagonists for the treatment of HIV infection: A review of compounds patented in 2006-2008. Expert Opinion on Therapeutic Patents 2010, 20:325-354.
123. 4 receptor channels expressed in anterior pituitary cells. American Journal of Physiology. Endocrinology and Metabolism 2010, 298:E644-E651.